

# MD7510 Clinical Presentation & Management in Diabetes: Glycaemic Control, New & Novel Therapies (DL)

View Online



[1]

'Diagnosis and management of type 1 diabetes in children, young people and adults | Guidance and guidelines | NICE' [Online]. Available: <https://www.nice.org.uk/guidance/cg15>

[2]

'Type 2 diabetes in adults: management | Guidance and guidelines | NICE' [Online]. Available: <https://www.nice.org.uk/guidance/ng28>

[3]

'Efficacy and Safety of Glucagon-like peptide-1 receptor agonists in type 2 diabetes Systematic review and mixed-treatment comparison analysis' [Online]. Available: <http://onlinelibrary.wiley.com.ezproxy3.lib.le.ac.uk/doi/10.1111/dom.12849/epdf>

[4]

'Obesity: identification, assessment and management | Guidance and guidelines | NICE' [Online]. Available: <https://www.nice.org.uk/guidance/cg189>

[5]

'Managing Older People with Type 2 Diabetes: IDF Global Guideline - International Federation on Ageing'. [Online]. Available: <https://www.ifa-fiv.org/managing-older-people-with-type-2-diabetes-idf-global-guideline/>

[6]

'NHS Evidence: an introduction'. [Online]. Available:  
[http://www.solent.nhs.uk/\\_store/documents/nhs\\_evidence\\_guide.pdf](http://www.solent.nhs.uk/_store/documents/nhs_evidence_guide.pdf)

[7]

R. I. G. Holt, C. Cockram, A. Flyvbjerg, and B. J. Goldstein, *Textbook of Diabetes*, 5th ed. Somerset: John Wiley & Sons, Incorporated, 2016 [Online]. Available:  
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

[8]

R. I. G. Holt, *Textbook of diabetes*, 4th ed. Chichester: Wiley-Blackwell, 2010 [Online]. Available: <http://ezproxy.lib.le.ac.uk/login?url=http://www.mylibrary.com?id=269077>

[9]

M. A. Atkinson, 'The Pathogenesis and Natural History of Type 1 Diabetes', *Cold Spring Harbor Perspectives in Medicine*, vol. 2, no. 11, pp. a007641–a007641, Nov. 2012, doi: 10.1101/cshperspect.a007641.

[10]

H. F. Jelinek, A. Stranieri, A. Yatsko, and S. Venkatraman, 'Data analytics identify glycosylated haemoglobin co-markers for type 2 diabetes mellitus diagnosis', *Computers in Biology and Medicine*, vol. 75, pp. 90–97, Aug. 2016, doi: 10.1016/j.combiomed.2016.05.005.

[11]

S M Attard, 'Implications of iron deficiency/anemia on the classification of diabetes using HbA1c', *Nutrition & Diabetes*, vol. 5, no. 6, 2015, doi: 10.1038/nutd.2015.16. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491857/>

[12]

V. T. Samuel and G. I. Shulman, 'Integrating Mechanisms for Insulin Resistance: Common Threads and Missing Links', *Cell*, vol. 148, no. 5, pp. 852–871, Mar. 2012, doi: 10.1016/j.cell.2012.02.017.

[13]

Beverley M Shields, 'Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature', *BMJ Open*, vol. 5, no. 11, 2015, doi: doi: 10.1136/bmjopen-2015-009088. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636628/?report=classic>

[14]

F. Zaccardi, D. R. Webb, T. Yates, and M. J. Davies, 'Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective', *Postgraduate Medical Journal*, vol. 92, no. 1084, pp. 63–69, Feb. 2016, doi: 10.1136/postgradmedj-2015-133281.

[15]

Anthony H. Barnett, Jenny Grice, *New Mechanisms in Glucose Control*. BMJ Books; 1 edition, 2013 [Online]. Available: <http://ezproxy.lib.le.ac.uk/login?url=http://lib.myilibrary.com?id=478133>

[16]

E. W. Gregg, 'The Changing Tides of the Type 2 Diabetes Epidemic—Smooth Sailing or Troubled Waters Ahead? Kelly West Award Lecture 2016', *Diabetes Care*, Aug. 2017, doi: 10.2337/dci16-0055.

[17]

R. I. G. Holt, C. Cockram, A. Flyvbjerg, and B. J. Goldstein, *Textbook of Diabetes*, 5th ed. Somerset: John Wiley & Sons, Incorporated, 2016 [Online]. Available: <http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

[18]

R. I. G. Holt, *Textbook of diabetes*, 4th ed. Chichester: Wiley-Blackwell, 2010 [Online]. Available: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

[19]

K. C. Copeland et al., 'Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents', *PEDIATRICS*, vol. 131, no. 2, pp. 364–382, Feb. 2013, doi: 10.1542/peds.2012-3494.

[20]

Kenneth Hodson, 'Gestational diabetes: emerging concepts in pathophysiology', *Obstetric Medicine*, vol. 3, no. 4, 2010, doi: doi: 10.1258/om.2010.100025. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989628/?report=classic>

[21]

Latika Sahu, 'Comparison of the American Diabetes Association and World Health Organization criteria for gestational diabetes mellitus and the outcomes of pregnancy', *Obstetric Medicine*, vol. 2, no. 4, 2009, doi: doi: 10.1258/om.2009.080049. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989660/?report=classic>

[22]

S. S. Schwartz, S. Epstein, B. E. Corkey, S. F. A. Grant, J. R. Gavin, and R. B. Aguilar, 'The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the  $\beta$ -Cell-Centric Classification Schema', *Diabetes Care*, vol. 39, no. 2, pp. 179–186, Feb. 2016, doi: 10.2337/dc15-1585.

[23]

C. J. Nolan, N. B. Ruderman, S. E. Kahn, O. Pedersen, and M. Prentki, 'Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes', *Diabetes*, vol. 64, no. 3, pp. 673–686, Mar. 2015, doi: 10.2337/db14-0694.

[24]

E. A. Gale, 'Is type 2 diabetes a category error?', *The Lancet*, vol. 381, no. 9881, pp. 1956–1957, Jun. 2013, doi: 10.1016/S0140-6736(12)62207-7.

[25]

C. Moreno-Castilla, D. Mauricio, and M. Hernandez, 'Role of Medical Nutrition Therapy in

the Management of Gestational Diabetes Mellitus', *Current Diabetes Reports*, vol. 16, no. 4, Apr. 2016, doi: 10.1007/s11892-016-0717-7.

[26]

E. Noctor and F. Dunne, 'Postnatal testing following gestational diabetes', *The Lancet Diabetes & Endocrinology*, vol. 3, no. 10, pp. 761–762, Oct. 2015, doi: 10.1016/S2213-8587(15)00322-8.

[27]

K. I. Birkeland, 'Hyperglycaemia in pregnancy: still a lot to learn', *The Lancet Diabetes & Endocrinology*, vol. 3, no. 10, pp. 752–753, Oct. 2015, doi: 10.1016/S2213-8587(15)00282-X.

[28]

Rinki Murphy, 'Monogenic diabetes and pregnancy', *Obstetric Medicine*, vol. 8, no. 3, 2015, doi: 10.1177/1753495X15590713. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935018/>

[29]

Z. A. Stewart et al., 'Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes', *New England Journal of Medicine*, vol. 375, no. 7, pp. 644–654, Aug. 2016, doi: 10.1056/NEJMoa1602494.

[30]

'Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period (NG3'. [Online]. Available: <https://www.nice.org.uk/guidance/ng3>

[31]

A. G. Jones and A. T. Hattersley, 'The clinical utility of C-peptide measurement in the care of patients with diabetes', *Diabetic Medicine*, vol. 30, no. 7, pp. 803–817, Jul. 2013, doi: 10.1111/dme.12159.

[32]

'Unit 3 – Special care groups: A practical guide to pregnancy complicated by diabetes - Diabetes & Primary Care'. [Online]. Available:  
<http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview>

[33]

J. Brown et al., 'Lifestyle interventions for the treatment of women with gestational diabetes', in *Cochrane Database of Systematic Reviews*, Chichester, UK: John Wiley & Sons, Ltd, 1996 [Online]. Available:  
<http://doi.wiley.com/10.1002/14651858.CD011970.pub2>

[34]

B. Rasouli et al., 'Serious life events and the risk of latent autoimmune diabetes in adults (LADA) and Type 2 diabetes', *Diabetic Medicine*, vol. 34, no. 9, pp. 1259–1263, Sep. 2017, doi: 10.1111/dme.13410.

[35]

M. Davies, D. Dahl, T. Heise, J. Kiljanski, and C. Mathieu, 'Introduction of biosimilar insulins in Europe', *Diabetic Medicine*, vol. 34, no. 10, pp. 1340–1353, Oct. 2017, doi: 10.1111/dme.13400.

[36]

N. E. Perrin, M. J. Davies, N. Robertson, F. J. Snoek, and K. Khunti, 'The prevalence of diabetes-specific emotional distress in people with Type 2 diabetes: a systematic review and meta-analysis', *Diabetic Medicine*, vol. 34, no. 11, pp. 1508–1520, Nov. 2017, doi: 10.1111/dme.13448.

[37]

R. I. G. Holt, C. Cockram, A. Flyvbjerg, and B. J. Goldstein, *Textbook of Diabetes*, 5th ed. Somerset: John Wiley & Sons, Incorporated, 2016 [Online]. Available:  
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

[38]

R. I. G. Holt, Textbook of diabetes, 4th ed. Chichester: Wiley-Blackwell, 2010 [Online]. Available: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

[39]

'Standards of Medical Care in Diabetes--2015: Summary of Revisions', Diabetes Care, vol. 38, no. Supplement\_1, pp. S4-S4, Jan. 2015, doi: 10.2337/dc15-S003.

[40]

'A Randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the anglo-Danish-Dutch Study of intensive Treatment in People with Screen-Detected Diabetes in Primary care (ADDITION-Europe) study.' [Online]. Available: <http://www.journalslibrary.nihr.ac.uk/hta/volume-20/issue-64#abstract>

[41]

Kamlesh Khunti, 'Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes', PLoS ONE, vol. 10, no. 9, 2015, doi: doi: 10.1371/journal.pone.0135702. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556656/?report=classic>

[42]

L. Tao et al., 'Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial', Diabetic Medicine, vol. 32, no. 7, pp. 907-919, Jul. 2015, doi: 10.1111/dme.12711.

[43]

L. J. Gray, K. Khunti, E. G. Wilmot, T. Yates, and M. J. Davies, 'External validation of two diabetes risk scores in a young UK South Asian population', Diabetes Research and Clinical Practice, vol. 104, no. 3, pp. 451-458, Jun. 2014, doi: 10.1016/j.diabres.2014.03.018.

[44]

L. J. Gray et al., 'Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance', *Diabetologia*, vol. 55, no. 12, pp. 3238–3244, Dec. 2012, doi: 10.1007/s00125-012-2725-8.

[45]

S. E. Inzucchi et al., 'Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes', *Diabetes Care*, vol. 38, no. 1, pp. 140–149, Jan. 2015, doi: 10.2337/dc14-2441.

[46]

'Guidelines'. [Online]. Available:  
<https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes>

[47]

R. I. G. Holt, C. Cockram, A. Flyvbjerg, and B. J. Goldstein, *Textbook of Diabetes*, 5th ed. Somerset: John Wiley & Sons, Incorporated, 2016 [Online]. Available:  
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

[48]

R. I. G. Holt, *Textbook of diabetes*, 4th ed. Chichester: Wiley-Blackwell, 2010 [Online]. Available: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

[49]

R. I. G. Holt, *Textbook of diabetes*, 4th ed. Chichester: Wiley-Blackwell, 2010 [Online]. Available: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

[50]

M. J. Davies et al., 'Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed



type 2 diabetes: cluster randomised controlled trial', *BMJ*, vol. 336, no. 7642, pp. 491–495, Mar. 2008, doi: 10.1136/bmj.39474.922025.BE.

[51]

B. C. Johnston et al., 'Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults', *JAMA*, vol. 312, no. 9, Sep. 2014, doi: 10.1001/jama.2014.10397.

[52]

S. Steven et al., 'Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders', *Diabetes Care*, vol. 39, no. 5, pp. 808–815, May 2016, doi: 10.2337/dc15-1942.

[53]

S. Steven and R. Taylor, 'Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes', *Diabetic Medicine*, vol. 32, no. 9, pp. 1149–1155, Sep. 2015, doi: 10.1111/dme.12722.

[54]

Amy Kennedy, 'Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis', *PLoS ONE*, vol. 8, no. 3, 2013, doi: doi: 10.1371/journal.pone.0058861. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598953/>

[55]

M. Chimen, A. Kennedy, K. Nirantharakumar, T. T. Pang, R. Andrews, and P. Narendran, 'What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review', *Diabetologia*, vol. 55, no. 3, pp. 542–551, Mar. 2012, doi: 10.1007/s00125-011-2403-2.

[56]

D. Umpierre, 'Physical Activity Advice Only or Structured Exercise Training and Association With HbA<sub>1c</sub> Levels in Type 2 Diabetes', *JAMA*, vol. 305, no. 17, May 2011,

doi: 10.1001/jama.2011.576.

[57]

L. Avery, D. Flynn, A. van Wersch, F. F. Sniehotta, and M. I. Trenell, 'Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions', *Diabetes Care*, vol. 35, no. 12, pp. 2681–2689, Dec. 2012, doi: 10.2337/dc11-2452.

[58]

V. W. Barry, M. Baruth, M. W. Beets, J. L. Durstine, J. Liu, and S. N. Blair, 'Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis', *Progress in Cardiovascular Diseases*, vol. 56, no. 4, pp. 382–390, Jan. 2014, doi: 10.1016/j.pcad.2013.09.002.

[59]

L. Qin, M. J. Knol, E. Corpeleijn, and R. P. Stolk, 'Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data', *European Journal of Epidemiology*, vol. 25, no. 1, pp. 5–12, Jan. 2010, doi: 10.1007/s10654-009-9395-y.

[60]

I.-M. Lee, 'Physical Activity and Weight Gain Prevention', *JAMA*, vol. 303, no. 12, Mar. 2010, doi: 10.1001/jama.2010.312.

[61]

John M Jakicic, 'Physical activity considerations for the treatment and prevention of obesity', *The American Journal of Clinical Nutrition*, vol. 82, no. 1, pp. 226S-229S, Jan. 2005 [Online]. Available: <http://ajcn.nutrition.org/content/82/1/226S>

[62]

I. Heinonen et al., 'Sedentary behaviours and obesity in adults: the Cardiovascular Risk in Young Finns Study', *BMJ Open*, vol. 3, no. 6, May 2013, doi: 10.1136/bmjopen-2013-002901.

[63]

J. F. Sallis et al., 'Progress in physical activity over the Olympic quadrennium', *The Lancet*, vol. 388, no. 10051, pp. 1325–1336, Sep. 2016, doi: 10.1016/S0140-6736(16)30581-5.

[64]

J. S. Yeh, R. F. Kushner, and G. D. Schiff, 'Obesity and Management of Weight Loss', *New England Journal of Medicine*, vol. 375, no. 12, pp. 1187–1189, Sep. 2016, doi: 10.1056/NEJMclde1515935.

[65]

Henson, Joseph, 'Associations of Sedentary Time with Fat Distribution in a High-Risk Population.', Nov. 2014 [Online]. Available: <https://ira.le.ac.uk/handle/2381/32505>

[66]

The Eatwell Guide. Public Health England, 2016 [Online]. Available: <https://www.gov.uk/government/publications/the-eatwell-guide>

[67]

'Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review) TA151, July 2008'. [Online]. Available: <http://www.nice.org.uk/guidance/ta151>

[68]

M. Hadjiconstantinou et al., 'Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis', *Journal of Medical Internet Research*, vol. 18, no. 10, Oct. 2016, doi: 10.2196/jmir.5991.

[69]

D. Young-Hyman, M. de Groot, F. Hill-Briggs, J. S. Gonzalez, K. Hood, and M. Peyrot, 'Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. *Diabetes Care* 2016;39:2126–2140', *Diabetes Care*, vol. 40, no. 2, p. 287.1-287, Feb. 2017, doi: 10.2337/dc17-er02.

[70]

M. Capehorn et al., 'Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights from a cross-national study (IntroDia )', *Diabetic Medicine*, Mar. 2017, doi: 10.1111/dme.13357.

[71]

Y. A. W. Hartman, H. J. Jansen, M. T. E. Hopman, C. J. Tack, and D. H. J. Thijssen, 'Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior', *Diabetes Care*, vol. 40, no. 9, pp. e120–e121, Sep. 2017, doi: 10.2337/dc17-0787.

[72]

D. M. Hessler et al., 'Diabetes distress is linked with worsening diabetes management over time in adults with Type 1 diabetes', *Diabetic Medicine*, vol. 34, no. 9, pp. 1228–1234, Sep. 2017, doi: 10.1111/dme.13381.

[73]

M. Ferrari, M. Dal Cin, and M. Steele, 'Self-compassion is associated with optimum self-care behaviour, medical outcomes and psychological well-being in a cross-sectional sample of adults with diabetes', *Diabetic Medicine*, vol. 34, no. 11, pp. 1546–1553, Nov. 2017, doi: 10.1111/dme.13451.

[74]

William H. Polonsky, Lawrence Fisher, Jay Earles, R. James Dudl, Joel Lees, Joseph Mullan, 'Assessing psychosocial distress in diabetes: development of the Diabetes Distress Scale', *Diabetes Care* [Online]. Available: [http://go.galegroup.com.ezproxy3.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT\\_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm&currentPosition=25&docId=GALE%7CA130282980&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA130282980&searchId=R15&userGroupName=leicester&inPS=true](http://go.galegroup.com.ezproxy3.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm&currentPosition=25&docId=GALE%7CA130282980&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA130282980&searchId=R15&userGroupName=leicester&inPS=true)

[75]

'Constructs of depression and distress in diabetes: time for an appraisal- ClinicalKey'.

[Online]. Available:

<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858715001357>

[76]

R. I. G. Holt, C. Cockram, A. Flyvbjerg, and B. J. Goldstein, *Textbook of Diabetes*, 5th ed. Somerset: John Wiley & Sons, Incorporated, 2016 [Online]. Available: <http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

[77]

R. I. G. Holt, *Textbook of diabetes*, 4th ed. Chichester: Wiley-Blackwell, 2010 [Online]. Available: <http://ezproxy.lib.le.ac.uk/login?url=http://www.mylibrary.com?id=269077>

[78]

B. Gallwitz et al., '2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial', *The Lancet*, vol. 380, no. 9840, pp. 475–483, Aug. 2012, doi: 10.1016/S0140-6736(12)60691-6.

[79]

C. V. Rizos, A. Kei, and M. S. Elisaf, 'The current role of thiazolidinediones in diabetes management', *Archives of Toxicology*, vol. 90, no. 8, pp. 1861–1881, Aug. 2016, doi: 10.1007/s00204-016-1737-4.

[80]

S. E. Nissen and K. Wolski, 'Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes', *New England Journal of Medicine*, vol. 356, no. 24, pp. 2457–2471, Jun. 2007, doi: 10.1056/NEJMoa072761.

[81]

M. Tanner, 'Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia', *Annals of Internal Medicine*, vol. 165, no. 4, Aug. 2016, doi: 10.7326/ACPJC-2016-165-4-020.

[82]

B. M. Mishriky, D. M. Cummings, and R. J. Tanenberg, 'The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis', *Diabetes Research and Clinical Practice*, vol. 109, no. 2, pp. 378–388, Aug. 2015, doi: 10.1016/j.diabres.2015.05.025.

[83]

W. L. Bennett et al., 'Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations', *Annals of Internal Medicine*, vol. 154, no. 9, May 2011, doi: 10.7326/0003-4819-154-9-201105030-00336.

[84]

Merlin C. Thomas, 'Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment', *Diabetes Therapy*, vol. 7, no. 3, 2016, doi: doi: 10.1007/s13300-016-0189-4. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014795/>

[85]

Paul Craddy, 'Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison', *Diabetes Therapy*, vol. 5, no. 1, 2014, doi: doi: 10.1007/s13300-014-0061-3. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065303/>

[86]

R. I. G. Holt, C. Cockram, A. Flyvbjerg, and B. J. Goldstein, *Textbook of Diabetes*, 5th ed. Somerset: John Wiley & Sons, Incorporated, 2016 [Online]. Available: <http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

[87]

R. I. G. Holt, *Textbook of diabetes*, 4th ed. Chichester: Wiley-Blackwell, 2010 [Online]. Available: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

[88]

B. Ryder et al., 'ABCD position statement on GLP-1 based therapies and pancreatic damage', *Practical Diabetes*, vol. 30, no. 9, pp. 388–391, Nov. 2013, doi: 10.1002/pdi.1816.

[89]

R. E. Amori, J. Lau, and A. G. Pittas, 'Efficacy and Safety of Incretin Therapy in Type 2 Diabetes', *JAMA*, vol. 298, no. 2, Jul. 2007, doi: 10.1001/jama.298.2.194.

[90]

J. B. Buse et al., 'Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)', *The Lancet*, vol. 374, no. 9683, pp. 39–47, Jul. 2009, doi: 10.1016/S0140-6736(09)60659-0.

[91]

'Type 2 diabetes: prevention in people at high risk | Guidance and guidelines | NICE' [Online]. Available: <http://www.nice.org.uk/guidance/PH38>

[92]

J. B. Buse et al., 'DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks', *Diabetes Care*, vol. 33, no. 6, pp. 1255–1261, Jun. 2010, doi: 10.2337/dc09-1914.

[93]

J. B. Buse et al., 'Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes', *Annals of Internal Medicine*, vol. 154, no. 2, Jan. 2011, doi: 10.7326/0003-4819-154-2-201101180-00300.

[94]

C. J. Bailey, J. L. Gross, A. Pieters, A. Bastien, and J. F. List, 'Effect of dapagliflozin in

patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial', *The Lancet*, vol. 375, no. 9733, pp. 2223–2233, Jun. 2010, doi: 10.1016/S0140-6736(10)60407-2.

[95]

M. Diamant et al., 'Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial', *The Lancet*, vol. 375, no. 9733, pp. 2234–2243, Jun. 2010, doi: 10.1016/S0140-6736(10)60406-0.

[96]

M. A. Nauck, G. Meininger, D. Sheng, L. Terranella, and P. P. Stein, 'Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial', *Diabetes, Obesity and Metabolism*, vol. 9, no. 2, pp. 194–205, Mar. 2007, doi: 10.1111/j.1463-1326.2006.00704.x.

[97]

'Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | 1-Recommendations | Guidance and guidelines | NICE' [Online]. Available: <https://www.nice.org.uk/guidance/ta390/chapter/1-Recommendations>

[98]

S. P. Marso et al., 'Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes', *New England Journal of Medicine*, Sep. 2016, doi: 10.1056/NEJMoa1607141.

[99]

M. A. Nauck and J. J. Meier, 'The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions', *The Lancet Diabetes & Endocrinology*, vol. 4, no. 6, pp. 525–536, Jun. 2016, doi: 10.1016/S2213-8587(15)00482-9.

[100]

'Type 2 diabetes: lixisenatide | Evidence-review | Advice | NICE' [Online]. Available:



<https://www.nice.org.uk/advice/esnm26/chapter/evidence-review>

[101]

'Dapagliflozin in combination therapy for treating type 2 diabetes June 2013'. [Online]. Available: <http://www.nice.org.uk/guidance/ta288>

[102]

'Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes | Guidance and guidelines TA 248 Feb 2015'. [Online]. Available: <https://www.nice.org.uk/guidance/ta248>

[103]

'Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010'. [Online]. Available: <https://www.nice.org.uk/guidance/ta203>

[104]

S. P. Marso et al., 'Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes', *New England Journal of Medicine*, vol. 375, no. 4, pp. 311–322, Jul. 2016, doi: 10.1056/NEJMoa1603827.

[105]

'Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes', *New England Journal of Medicine*, vol. 375, no. 18, pp. 1797–1799, Nov. 2016, doi: 10.1056/NEJMc1611289.

[106]

C. Wanner et al., 'Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes', *New England Journal of Medicine*, vol. 375, no. 4, pp. 323–334, Jul. 2016, doi: 10.1056/NEJMoa1515920.

[107]

'Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes', *New England Journal of Medicine*, vol. 375, no. 18, pp. 1799–1802, Nov. 2016, doi: 10.1056/NEJMc1611290.

[108]

H. Courtney, R. Nayar, C. Rajeswaran, and R. Jandhyala, 'Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists', *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, vol. Volume 10, pp. 79–87, Mar. 2017, doi: 10.2147/DMSO.S126763.

[109]

J. B. Green et al., 'Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes', *New England Journal of Medicine*, vol. 373, no. 3, pp. 232–242, Jul. 2015, doi: 10.1056/NEJMoa1501352.

[110]

M. E. Rotz, V. S. Ganetsky, S. Sen, and T. F. Thomas, 'Implications of incretin-based therapies on cardiovascular disease', *International Journal of Clinical Practice*, vol. 69, no. 5, pp. 531–549, May 2015, doi: 10.1111/ijcp.12572.

[111]

S. P. Marso et al., 'Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes', *New England Journal of Medicine*, vol. 375, no. 4, pp. 311–322, Jul. 2016, doi: 10.1056/NEJMoa1603827.

[112]

P. A. Levin, H. Nguyen, E. Wittbrodt, and S. C. Kim, 'Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research', *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, vol. Volume 10, pp. 123–139, Apr. 2017, doi: 10.2147/DMSO.S130834.

[113]

R. I. G. Holt, C. Cockram, A. Flyvbjerg, and B. J. Goldstein, *Textbook of Diabetes*, 5th ed. Somerset: John Wiley & Sons, Incorporated, 2016 [Online]. Available:

<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

[114]

R. I. G. Holt, Textbook of diabetes, 4th ed. Chichester: Wiley-Blackwell, 2010 [Online]. Available: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

[115]

D. R. Leff and D. Heath, 'Surgery for obesity in adulthood', *BMJ*, vol. 339, no. sep22 1, pp. b3402–b3402, Sep. 2009, doi: 10.1136/bmj.b3402.

[116]

P. R. Schauer et al., 'Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes', *New England Journal of Medicine*, vol. 366, no. 17, pp. 1567–1576, Apr. 2012, doi: 10.1056/NEJMoa1200225.

[117]

M. C. Riddle et al., 'Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)', *Diabetes Care*, vol. 36, no. 9, pp. 2489–2496, Sep. 2013, doi: 10.2337/dc12-2454.

[118]

L. Sjöström et al., 'Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery', *New England Journal of Medicine*, vol. 351, no. 26, pp. 2683–2693, Dec. 2004, doi: 10.1056/NEJMoa035622.

[119]

S. J. Persaud and P. M. Jones, 'A Wake-up Call for Type 2 Diabetes?', *New England Journal of Medicine*, vol. 375, no. 11, pp. 1090–1092, Sep. 2016, doi: 10.1056/NEJMcibr1607950.

[120]

J. A. Fagin and S. A. Wells, 'Biologic and Clinical Perspectives on Thyroid Cancer', *New England Journal of Medicine*, vol. 375, no. 11, pp. 1054–1067, Sep. 2016, doi: 10.1056/NEJMra1501993.

[121]

'National Obesity Observatory'. [Online]. Available: <http://www.noo.org.uk>

[122]

P. R. Schauer et al., 'Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes', *New England Journal of Medicine*, vol. 376, no. 7, pp. 641–651, Feb. 2017, doi: 10.1056/NEJMoa1600869.

[123]

S. H. Min, J.-H. Yoon, S. Hahn, and Y. M. Cho, 'Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis', *Diabetes/Metabolism Research and Reviews*, vol. 33, no. 1, Jan. 2017, doi: 10.1002/dmrr.2818.

[124]

K. M. Dungan et al., 'Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial', *The Lancet*, vol. 384, no. 9951, pp. 1349–1357, Oct. 2014, doi: 10.1016/S0140-6736(14)60976-4.

[125]

M. Nauck, R. S. Weinstock, G. E. Umpierrez, B. Guerci, Z. Skrivanek, and Z. Milicevic, 'Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)', *Diabetes Care*, vol. 37, no. 8, pp. 2149–2158, Aug. 2014, doi: 10.2337/dc13-2761.

[126]

P. R. Schauer et al., 'Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes', *New England Journal of Medicine*, vol. 376, no. 7, pp. 641–651, Feb. 2017, doi: 10.1056/NEJMoa1600869.

[127]

M. A. Bethel et al., 'Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)', *Diabetes Care*, vol. 40, no. 4, pp. 494–501, Apr. 2017, doi: 10.2337/dc16-1135.

[128]

R. I. G. Holt, C. Cockram, A. Flyvbjerg, and B. J. Goldstein, *Textbook of Diabetes*, 5th ed. Somerset: John Wiley & Sons, Incorporated, 2016 [Online]. Available: <http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

[129]

R. I. G. Holt, *Textbook of diabetes*, 4th ed. Chichester: Wiley-Blackwell, 2010 [Online]. Available: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

[130]

R. M. Bergenstal et al., 'Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes', *New England Journal of Medicine*, vol. 363, no. 4, pp. 311–320, Jul. 2010, doi: 10.1056/NEJMoa1002853.

[131]

P. Choudhary, N. R. Parrott, L. Birtles, and M. K. Rutter, 'Islet cell transplantation: current status in the UK (2012)', *Practical Diabetes*, vol. 29, no. 7, pp. 280–285, Sep. 2012, doi: 10.1002/pdi.1707.

[132]

J. C. Pickup, 'Insulin-Pump Therapy for Type 1 Diabetes Mellitus', *New England Journal of Medicine*, vol. 366, no. 17, pp. 1616–1624, Apr. 2012, doi: 10.1056/NEJMct1113948.

[133]

P. Srinivasan, G. C. Huang, S. A. Amiel, and N. D. Heaton, 'Islet cell transplantation', *Postgraduate Medical Journal*, vol. 83, no. 978, pp. 224–229, Apr. 2007, doi: 10.1136/pgmj.2006.053447.

[134]

'Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010'. [Online]. Available: <https://www.nice.org.uk/guidance/ta203>

[135]

M. Villani, B. de Courten, and S. Zoungas, 'Emergency treatment of hypoglycaemia: a guideline and evidence review', *Diabetic Medicine*, vol. 34, no. 9, pp. 1205–1211, Sep. 2017, doi: 10.1111/dme.13379.

[136]

K. K. Dhatariya, C. Skedgel, and R. Fordham, 'The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use', *Diabetic Medicine*, vol. 34, no. 10, pp. 1361–1366, Oct. 2017, doi: 10.1111/dme.13427.

[137]

L. Leelarathna et al., 'Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes', *Diabetic Medicine*, vol. 34, no. 10, pp. 1372–1379, Oct. 2017, doi: 10.1111/dme.13412.

[138]

T. Yates and M. J. Davies, 'Physical activity and Type 1 diabetes: an underused therapy', *Diabetic Medicine*, vol. 34, no. 11, pp. 1498–1499, Nov. 2017, doi: 10.1111/dme.13445.

[139]

P. Narendran et al., 'Exercise to preserve  $\beta$ -cell function in recent-onset Type 1 diabetes mellitus (EXTOD) - a randomized controlled pilot trial', *Diabetic Medicine*, vol. 34, no. 11,

pp. 1521–1531, Nov. 2017, doi: 10.1111/dme.13439.

[140]

R. I. G. Holt, C. Cockram, A. Flyvbjerg, and B. J. Goldstein, Textbook of Diabetes, 5th ed. Somerset: John Wiley & Sons, Incorporated, 2016 [Online]. Available: <http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

[141]

R. I. G. Holt, Textbook of diabetes, 4th ed. Chichester: Wiley-Blackwell, 2010 [Online]. Available: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

[142]

'Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring', Journal of diabetes science and technology (Online), vol. 3, no. 4 [Online]. Available: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769951/>

[143]

'Minimizing Hypoglycemia in Diabetes: Table 1', Diabetes Care, vol. 38, no. 8, pp. 1583–1591, Aug. 2015, doi: 10.2337/dc15-0279.

[144]

'[ARCHIVED CONTENT] Medicines management: Everybody's business : Department of Health - Publications and statistics'. [Online]. Available: [http://webarchive.nationalarchives.gov.uk/20080205132320/http://dh.gov.uk/en/publication/sandstatistics/publications/publicationspolicyandguidance/dh\\_082200](http://webarchive.nationalarchives.gov.uk/20080205132320/http://dh.gov.uk/en/publication/sandstatistics/publications/publicationspolicyandguidance/dh_082200)

[145]

'Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. CG76, Jan 2009'. [Online]. Available: <https://www.nice.org.uk/guidance/cg76>

[146]

J. Grammes, W. Stock, C. G. Mann, E. M. Flynn, and T. Kubiak, 'Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus', *Diabetic Medicine*, Aug. 2017, doi: 10.1111/dme.13506.

[147]

S. Sivasubramaniam, S. A. Amiel, and P. Choudhary, 'Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range', *Diabetic Medicine*, vol. 34, no. 10, pp. 1456–1460, Oct. 2017, doi: 10.1111/dme.13438.

[148]

A. F. Vloemans et al., 'Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study', *Diabetic Medicine*, vol. 34, no. 10, pp. 1470–1476, Oct. 2017, doi: 10.1111/dme.13429.

[149]

I. Harman-Boehm, 'Continuous glucose monitoring in type 2 diabetes', *Diabetes Research and Clinical Practice*, vol. 82, pp. S118–S121, Dec. 2008, doi: 10.1016/j.diabres.2008.09.051.

[150]

Bailey, Stephen, *Academic Writing : A Handbook for International Students*. [Online]. Available: <http://lib.myilibrary.com.ezproxy4.lib.le.ac.uk/Open.aspx?id=310467>

[151]

P. Creme and M. R. Lea, *Writing At University: A Guide For Students*, 3rd ed. Maidenhead: McGraw-Hill Education, 2008 [Online]. Available: <https://ebookcentral.proquest.com/lib/leicester/detail.action?pq-origsite=primo&docID=345134>